AxoGen, Inc. (AXGN) Stock

AxoGen, Inc. (AXGN) is a Healthcare stock trading at $44.91 (as of 2026-06-18), with a market capitalization of $2.16B and a trailing P/E of -67.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AxoGen, Inc. develops and sells surgical products used in the repair of peripheral nerve injuries, including biologically derived grafts and extracellular matrix–based aids. Its offerings include nerve grafts and coaptation, protection, and separation products, as well as a processed human umbilical cord membrane used as a resorbable soft-tissue covering, for use by surgeons treating nerve damage or transection.

Valuation — source: SEC EDGAR (first-party)
Price	$44.91
Market Cap	$2.16B
P/E Ratio	-67.2
EV / EBITDA	-886.5
Price / Book	9.34
Price / Sales	9.60
DCF Value (model)	$-1.13
DCF Upside vs Price	-102.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$225.21M
Net Margin	-7.0%
Return on Equity	-12.8%
Current Ratio	7.10
Revenue Growth (YoY)	26.6%
EPS Growth (YoY)	375.0%
FCF Growth (YoY)	-90.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	14.55 (safe)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-67.2
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-420.6%
vs Industry	-311.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	First Light Asset Management, LLC ($132.61M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Michael D. Dale
Employees	451
Country	US
IPO Date	1986-12-17

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.